Stocks of Schrodinger Inc (NASDAQ:SDGR) traded higher last session on Wall Street, down -14.44% to $22.83.
SDGR stock price is now -2.32% away from the 50-day moving average and 6.67% away from the 200-day moving average. The market capitalization of the company currently stands at $1.68B.
With the price target of $29, Leerink Partners recently initiated with Outperform rating for Schrodinger Inc (NASDAQ: SDGR). On December 05, 2023, KeyBanc Capital Markets recently initiated its ‘Overweight’ rating on the stock quoting a target price of $38, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Akinsanya Karen, President of R&D, Therapeutics sold 16,723 shares of the company’s stock on Apr 14 ’25. The stock was sold for $419,570 at an average price of $25.09. Upon completion of the transaction, the President of R&D, Therapeutics now directly owns 15,625 shares in the company, valued at $0.36 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 14 ’25, Officer Karen Akinsanya bought 16,723 shares of the business’s stock. A total of $409,546 was incurred on buying the stock at an average price of $24.49. A total of 14.96% of the company’s stock is owned by insiders.
During the past 12 months, Schrodinger Inc has had a low of $16.60 and a high of $28.47. As of last week, the company has a debt-to-equity ratio of 0.31, a current ratio of 3.45, and a quick ratio of 3.45.
The net profit margin was -83.39% and return on equity was -43.33% for SDGR. For the current quarter, analysts expect SDGR to generate $52.03M in revenue.
